Gina Nugent

Biotech communications professional, runner and mom.

[Immuneering Corp @Immuneering]

Proud to see our research featured on the cover of @CR_AACR! The study highlights atebimetinib's broad antitumor activity in RAS-mutant cancer models and the science driving our work to advance new treatment approaches for pancreatic cancer. https://t.co/OK83kDsplf

[Eledon Pharmaceuticals, Inc. @Eledon_Pharma]

"Within six months, I was fully recovered. I was working longer hours, doing better. I had a lot more fun with my life. It was just great." Jeff Nelson shares his #KidneyTransplant journey in our latest #TransplantReflections story with @nkf: https://t.co/EsmgBgf8jU

[Immuneering Corp @Immuneering]

Can we change the outlook for people facing pancreatic cancer?
Dr. Meredith Pelster of @SarahCannonDocs discusses the Phase 3 #MAPKeeper301 trial evaluating atebimetinib + chemo in 1L pancreatic cancer in a new @OncLive interview. Watch: https://t.co/lRjQOdYypx

[Immuneering Corp @Immuneering]

Today is cancer cachexia awareness day. Raising awareness for the wasting syndrome that touches up to 80% of people with advanced cancer.

Learn more about cancer cachexia here: https://t.co/ltZCbICDr0

#CancerCachexiaAwarenessDay #CCAD

[Immuneering Corp @Immuneering]

$IMRX announced a significant milestone with dosing of the 1st patient in our global, pivotal, Phase 3 MAPKeeper 301 trial of atebimetinib + mGNP (compared to GNP alone) in 1L #PancreaticCancer.

Read our PR here for more info: https://t.co/RxkQuUUhlR

[Immuneering Corp @Immuneering]

Excited to welcome Andrew Gengos as Immuneering’s new CFO! Formerly at Terns Pharmaceuticals, he’ll lead finance strategy, IR & BD as we advance atebimetinib in the Ph 3 MAPKeeper 301 trial in 1L pancreatic cancer and progress our broader pipeline. Read more: https://t.co/qJ8wcCtU1y

[Immuneering Corp @Immuneering]

We’re pleased to see our recent clinical data featured in @BioWorld, highlighting the growing momentum in the #PancreaticCancer treatment landscape.
Read more: https://t.co/qXHoljx9MD

#Oncology #Biotech #ASCO

[BiotechTV @BiotechTV]

𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔: @Immuneering presented an update of the P2 trial of its deep cyclic inhibitor of MEK in 1L pancreatic cancer at ASCO. CEO Ben Zeskind argues why competitor data should not overshadow this. $IMRX #ASCO26

Full video: https://t.co/EIrfbeBm3H

[Immuneering Corp @Immuneering]

$IMRX CEO @BenZeskind spoke with @BradLoncar of @BiotechTV from #ASCO about the compelling data behind our lead program atebimetinib in combination with chemo, demonstrating 17.3 mOS and a favorable tolerability profile.

Watch the full interview: https://t.co/Y1rbl3u6JB

[Immuneering Corp @Immuneering]

Appreciate @BioSpace highlighting our latest #PancreaticCancer data presented today at #ASCO2026 in which atebimetinib + chemo demonstrated 17.3 months median overall survival along with a favorable tolerability profile. Read more: https://t.co/mZrRSbwxcn

[BioSpace @biospace]

In addition to eliciting 17.3 months median overall survival vs. 8.5 months for patients given standard of care treatment in a prior study, Immuneering’s atebimetinib demonstrated a robust tolerability profile.

https://t.co/3nOn7LK0HI

[Gina Nugent @ginanugent3]

More good news for pancreatic cancer patients!

[Immuneering Corp @Immuneering]

Topline data from 55 ptnts in $IMRX Phase 2a trial of atebimetinib + mGnP demonstrates 17.3 mth median overall survival in 1L #PancreaticCancer - more than 2x standard of care. Full data to be presented on June 1st at the #ASCO2026. Learn more here: https://t.co/zLdlIApPC0

[Gina Nugent @ginanugent3]

Check out this @brewmarkets Daily podcast hosted by @AnnBerry_NYC in which $IMRX CEO @BenZeskind explains the company's unique approach to treating pancreatic cancer.

[Immuneering Corp @Immuneering]

We’re excited to share a recent conversation featuring $IMRX CEO @BenZeskind on @Brewmarkets podcast, hosted by @AnnBerry_NYC. Ben highlights both the science behind our platform and the broader opportunity to rethink how cancer is treated.

https://t.co/AwKwWBae4x

[Gina Nugent @ginanugent3]

Good news for patients with #PancreaticCancer! Congrats to $IMRX team.

[Immuneering Corp @Immuneering]

$IMRX is marking a strong start to the year, reporting an exceptional 64% overall survival at 12mths for atebimetinib + chemo in 1st line #PancreaticCancer patients – nearly double the standard of care benchmark. Read our press release to learn more: https://t.co/7ncokXA0Dt

[Gina Nugent @ginanugent3]

Congrats to the Immuneering team - amazing progress!

[Immuneering Corp @Immuneering]

Momentum continues for atebimetinib in 1st-line #PancreaticCancer! With FDA and EMA alignment secured, we are advancing toward dosing the first patient in our global Phase 3 registrational trial, “MAPKeeper 301” in mid-2026. Read more here: https://t.co/mvFbx4RUVq

[Immuneering Corp @Immuneering]

Momentum continues for atebimetinib in 1st-line #PancreaticCancer! With FDA and EMA alignment secured, we are advancing toward dosing the first patient in our global Phase 3 registrational trial, “MAPKeeper 301” in mid-2026. Read more here: https://t.co/mvFbx4RUVq

[Gina Nugent @ginanugent3]

Amazing innovations in the transplantation field!

[Eledon Pharmaceuticals, Inc. @Eledon_Pharma]

Outstanding to see Tim Andrews throw the first pitch at @fenwaypark, just months after receiving a pig kidney #transplant - a groundbreaking procedure we proudly supported with our investigational #immunosuppression therapy #tegoprubart. Watch: https://t.co/exJoiovSWm $ELDN @WCVB

[Gina Nugent @ginanugent3]

Congrats to the Immuneering team on this new, positive Phase 2a data for atebimetinib (IMM-1-104) in first-line pancreatic cancer!

[Immuneering Corp @Immuneering]

We are pleased to report positive overall survival data from our ongoing Phase 2a trial evaluating our lead product candidate atebimetinib in first-line patients with #PancreaticCancer. Read our press release to learn more: https://t.co/1uQgYVbB8I $IMRX

[Gina Nugent @ginanugent3]

Amazing achievement. Congrats to the @Eledon_Pharma team!

[Eledon Pharmaceuticals, Inc. @Eledon_Pharma]

Today we announced that our investigational therapy was used as a key component of the #immunosuppression regimen for the second patient to receive a transplanted kidney from a genetically modified pig in a procedure conducted by @MassGeneralNews: https://t.co/LofXpV3cNk $ELDN

[Gina Nugent @ginanugent3]

This morning @Immuneering announced a clinical supply agreement with @Regeneron to evaluate IMM-1-104 in combo with Libtayo in NSCLC.

[Immuneering Corp @Immuneering]

Today $IMRX announced a clinical supply agreement with @Regeneron, supporting evaluation of IMM-1-104 in combo with #Libtayo in patients with #RASmutant #NSCLC.
Read the press release here: https://t.co/oQ4KZPPMyL